Bio-Technology General (BTG)
(Norwich, UK, 13/07/2018) – One of the first biologic companies in Israel, Bio-Technology General (BTG) remains a pioneer in the development, production and manufacturing of exceptional human health products.
Renowned for driving high quality across its production lines, the company’s recent $15mn investment by parent company, Ferring Pharmaceuticals, will allow the company to further scale, whilst strengthening its BTG’s supply chain operations.
“We need to ensure medicine supplied is high quality, which means controlled shipment and logistics routes, making sure we have the right safety stops for each market,” explains Alon Ben Dror, Head of Supply Chain, BTG.
By combining its supply chain and IT operations, BTG have invested in a number of key technologies to enhance the shipping process, whilst reducing inventory and cycle time.
Additionally, the business is also set to ramp up production of new products and services, such as fertility treatment, Rekovelle, to further cater to ongoing global demand.
“This product is going to be manufactured at several sites at BTG, and we will also have a backup site in Switzerland. This investment will enable us to enhance the biotech process,” adds Ben Dror.